BOCA RATON, Fla., Oct. 31, 2024 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage inflammation and immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today announces its financial results for the quarter ended September 30, 2024 and provides a business update. Q3 2024 and Recent Corporate Highlights   DN-TNF Platform Highlights (XPro™): Announced completion enrollment for its Phase 2 Alzheimer’s Disease (“A ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-38793 | --- | --- | --- | |------------------------------------------------------|--------------------------------------------------------------------------- ...

Core Insights - INmune Bio, Inc. has published a study demonstrating that XPro1595 promotes remyelination in an animal model of demyelinating disease, with implications for various CNS diseases including Alzheimer's [1][2] - The study identifies soluble TNF as a critical cytokine checkpoint that can convert microglia from a reparative to a damaging state, suggesting that blocking soluble TNF may be a promising strategy for treating demyelinating diseases [2] - INmune Bio anticipates reporting top-line cognitive results from an ongoing Phase II trial in early Alzheimer's patients in the first half of 2025 [2] Company Overview - INmune Bio, Inc. is a clinical-stage biotechnology company focused on developing treatments that target the innate immune system to combat diseases [4] - The company has two product platforms in clinical trials: the Dominant-Negative Tumor Necrosis Factor (DNTNF) platform and the Natural Killer Cell Priming Platform [4] - XPro1595 is the first product from the DNTNF platform, currently in trials for Mild Alzheimer's disease, with plans to explore additional indications such as treatment-resistant depression and oncology [4] Demyelination in Alzheimer's Disease - Research indicates that demyelination occurs in brain regions critical for cognition in Alzheimer's patients, often associated with amyloid-beta plaques [3] - Myelin loss may precede or accompany classic pathological changes in Alzheimer's, with alterations in myelin density detectable before typical symptoms arise [3] - Mechanisms of myelin damage in Alzheimer's involve oligodendrocyte dysfunction, contributing to a feedback loop that exacerbates both myelin loss and neurodegeneration [3]

Management to host conference call and webcast at 4:30 pm ET on that day Boca Raton, Florida, Oct. 24, 2024 (GLOBE NEWSWIRE) --  INmune Bio Inc. (NASDAQ: INMB) (the “Company”),  a clinical-stage inflammation and immunology company targeting microglial activation and neuroinflammation as a cause of Alzheimer’s Disease (AD), today announced that it will host a conference call on Thursday October 31, 2024, at 4:30pm EDT to discuss results for its quarter ended September 30, 2024 and to provide a corporate upda ...

Core Viewpoint - INmune Bio Inc. is participating in the Maxim Healthcare Virtual Summit from October 15-17, 2024, to discuss its clinical-stage developments targeting neuroinflammation and Alzheimer's Disease [1][2]. Company Overview - INmune Bio Inc. is a publicly traded clinical-stage biotechnology company focused on developing treatments that target the innate immune system to combat diseases [2]. - The company has two main product platforms in clinical trials: - The Dominant-Negative Tumor Necrosis Factor (DN-TNF) platform, which includes XPRO, aimed at treating Mild Alzheimer's disease and potentially treatment-resistant depression and oncology in the future [2]. - The Natural Killer Cell Priming Platform, featuring INKmune™, designed to prime NK cells for cancer treatment, currently enrolling patients in a Phase I/II trial for metastatic castrate-resistant prostate cancer [2].

This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe to, I'm currently offering a two-week free trial period for subscribers to take advantage of. My service offers a deep-dive analysis of many pharmaceutical companies. The Biotech Analysis Central SA marketplace is $49 per month, but for those who sign up for the yearly plan will be able to take advantage of a 33. ...

BOCA RATON, Fla., Sept. 26, 2024 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the "Company"), a clinical-stage immunology and inflammation company, continues to advance its Natural Killer (NK) cell therapy, INKmune™, in a Phase I/II trial (the "CaRe PC" trial) for men with metastatic CastrationResistant Prostate Cancer (mCRPC). The Company is pleased to announce initial results from the first patient cohort in the trial. Mark Lowdell, CSO and inventor of INKmune™, said, "The enrollment of the first c ...

Core Insights - INmune Bio Inc. announced exceptional performance of the EMACC cognitive measure in its AD02 Phase II Alzheimer's Disease trial, showing a significant correlation with the CDR-SB endpoint [1][3][4] Group 1: EMACC Performance - The analysis confirmed a highly significant correlation (p<0.001) between baseline scores on EMACC and CDR-SB, which is the most commonly used clinical rating scale in Alzheimer's Disease registration studies [3] - EMACC demonstrated a reliability correlation of 0.93 when measured during screening and at the first study visit before treatment, indicating high precision and robustness [3] - EMACC effectively differentiated between patients with prodromal AD (CDR global rating of 0.5) and mild dementia (CDR rating of 1.0), with an effect size (Cohen's d) of 0.87 (p<.0001) [3] Group 2: Clinical Trial Insights - The novel design elements in the AD02 Phase II trial are believed to significantly de-risk the clinical program compared to traditional trial designs in Alzheimer's drug development [4] - EMACC is positioned as the primary endpoint in the trial, which aims to measure cognitive changes in early AD patients with biomarkers of inflammation [4] - Enrollment is expected to be completed by the end of the current quarter, with topline data anticipated approximately six months after the last patient is enrolled [4] Group 3: About EMACC - EMACC is an empirically derived cognitive measure that combines standardized neuropsychological tests, showing the greatest sensitivity to change in early Alzheimer's Disease patients over two years [5] - The performance characteristics of EMACC were first reported by Biogen at CTAD in 2021 and were found to be strongly associated with biological markers of inflammation [5] Group 4: Company Overview - INmune Bio Inc. is a clinical-stage biotechnology company focused on developing treatments targeting the innate immune system to combat diseases [9] - The company has two product platforms in clinical trials: the DN-TNF product platform and the Natural Killer Cell Priming Platform, aimed at treating various diseases including cancer and chronic inflammation [9]

Boca Raton, Florida, Sept. 13, 2024 (GLOBE NEWSWIRE) -- INmune Bio Inc. (Nasdaq: INMB) (the "Company" or "INmune Bio"), a clinical-stage inflammation and immunology company focused on developing treatments that harness a patient's innate immune system to fight disease, today announced it has entered into securities purchase agreements with new and existing institutional investors and certain directors and officers and employees of the Company (the directors and officers and employees herein referred to as t ...

Core Insights - INmune Bio Inc. presented significant findings on the effects of XPro™ on synaptic proteins and pathways at the Alzheimer's Association International Conference (AAIC) [1][2] - The analysis showed that a 12-week treatment with XPro™ led to notable changes in synaptic proteins crucial for neuron communication [2][3] - The company is currently conducting a phase 2 clinical trial for mild to moderate Alzheimer's patients, with top-line results expected in early 2025 [4] Company Overview - INmune Bio Inc. is a clinical-stage company focused on inflammation and immunology, developing treatments that leverage the innate immune system [1][6] - The company has two main product platforms in clinical trials: the Dominant-Negative Tumor Necrosis Factor (DNTNF) platform and the Natural Killer Cell Priming Platform [6] - XPro™ is a next-generation TNF inhibitor that neutralizes soluble TNF without affecting trans-membrane TNF or TNF receptors, potentially reducing neuroinflammation without immunosuppression [5][6] Research Findings - The loss of synapses in Alzheimer's disease has severe consequences, and XPro™ has shown a robust effect on proteins and pathways that regulate synapse formation [3][4] - The treatment's impact on synaptic proteins aligns with previous observations in preclinical models, suggesting a restoration of normal immune function [3][4] - The company believes that the biological effects observed may lead to cognitive benefits, which are currently being tested in ongoing trials [4]